As an example, tigecycline has been used against gastric cancer and multiple myeloma preclinical models and induced cellular autophagy through the conversion of microtubule-associated protein light chain 3-I (LC3I) to LC3II and the fragmentation of autophagic substrate sequestrosome-1 (SQSTM1)/p62 [50,53]. This evidence concerns the gene SQSTM1 and plasma cell myeloma.